Lv1
30 积分 2022-07-29 加入
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
20天前
已完结
MA02.05 Liquid Biopsy in BRAF V600E NSCLC Treated With Dabrafenib Plus Trametinib: Final Analysis of LiBRA Study (GOIRC-03-2020)
2个月前
已关闭
Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology
4个月前
已完结
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe
4个月前
已完结
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer
4个月前
已完结
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe
4个月前
已关闭
BRAF V600突变型非小细胞肺癌的治疗进展
4个月前
已完结
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
7个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
7个月前
已完结
EP.12.36 Data Visualization of Treatment Patterns in Adults With BRAFV600EMutant mNSCLC in Real-World Settings
7个月前
已关闭
皖公网安备34019202002308
